Follow
Peter Boström
Peter Boström
Turku University Hospital
Verified email at tyks.fi
Title
Cited by
Cited by
Year
Genomic predictors of outcome in prostate cancer
PJ Boström, AS Bjartell, JWF Catto, SE Eggener, H Lilja, S Loeb, ...
European urology 68 (6), 1033-1044, 2015
2112015
Risk factors for mortality and morbidity related to radical cystectomy
PJ Boström, J Kössi, M Laato, M Nurmi
BJU international 103 (2), 191-196, 2009
1892009
Nutraceuticals and prostate cancer prevention: a current review
G Trottier, PJ Boström, N Lawrentschuk, NE Fleshner
Nature Reviews Urology 7 (1), 21-30, 2010
1492010
Radiomic features for prostate cancer detection on MRI differ between the transition and peripheral zones: preliminary findings from a multi‐institutional study
SB Ginsburg, A Algohary, S Pahwa, V Gulani, L Ponsky, HJ Aronen, ...
Journal of Magnetic Resonance Imaging 46 (1), 184-193, 2017
1332017
Radiomics and machine learning of multisequence multiparametric prostate MRI: Towards improved non-invasive prostate cancer characterization
J Toivonen, I Montoya Perez, P Movahedi, H Merisaari, M Pesola, ...
PLoS One 14 (7), e0217702, 2019
972019
Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial)
I Jambor, PJ Boström, P Taimen, K Syvänen, E Kähkönen, M Kallajoki, ...
Journal of Magnetic Resonance Imaging 46 (4), 1089-1095, 2017
962017
Randomised trial of adjuvant radiotherapy following radical prostatectomy versus radical prostatectomy alone in prostate cancer patients with positive margins or extracapsular …
G Hackman, K Taari, TL Tammela, M Matikainen, M Kouri, T Joensuu, ...
European urology 76 (5), 586-595, 2019
942019
Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort
G Trottier, MJ Roobol, N Lawrentschuk, PJ Boström, KA Fernandes, ...
BJU international 108 (8b), E237-E244, 2011
942011
Evaluation of different mathematical models for diffusion‐weighted imaging of normal prostate and prostate cancer using high b‐values: a repeatability study
I Jambor, H Merisaari, P Taimen, P Boström, H Minn, M Pesola, ...
Magnetic resonance in medicine 73 (5), 1988-1998, 2015
902015
Expression of collagenase‐3 (matrix metalloproteinase‐13) in transitional‐cell carcinoma of the urinary bladder
PJ Boström, L Ravanti, N Reunanen, V Aaltonen, KO Söderström, ...
International journal of cancer 88 (3), 417-423, 2000
892000
Mathematical models for diffusion‐weighted imaging of prostate cancer using b values up to 2000 s/mm2: Correlation with Gleason score and repeatability of …
J Toivonen, H Merisaari, M Pesola, P Taimen, PJ Boström, T Pahikkala, ...
Magnetic resonance in medicine 74 (4), 1116-1124, 2015
832015
Fitting methods for intravoxel incoherent motion imaging of prostate cancer on region of interest level: Repeatability and gleason score prediction
H Merisaari, P Movahedi, IM Perez, J Toivonen, M Pesola, P Taimen, ...
Magnetic resonance in medicine 77 (3), 1249-1264, 2017
772017
A prospective comparison of 18F-prostate-specific membrane antigen-1007 positron emission tomography computed tomography, whole-body 1.5 T magnetic resonance imaging with …
M Anttinen, O Ettala, S Malaspina, I Jambor, M Sandell, S Kajander, ...
European urology oncology 4 (4), 635-644, 2021
762021
Tumor-associated macrophages provide significant prognostic information in urothelial bladder cancer
MM Boström, H Irjala, T Mirtti, P Taimen, T Kauko, A Ålgars, S Jalkanen, ...
PloS one 10 (7), e0133552, 2015
752015
Prospective evaluation of 18F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial)
I Jambor, A Kuisma, E Kähkönen, J Kemppainen, H Merisaari, O Eskola, ...
European journal of nuclear medicine and molecular imaging 45, 355-364, 2018
732018
Combined use of prostate-specific antigen density and magnetic resonance imaging for prostate biopsy decision planning: a retrospective multi-institutional study using the …
UG Falagario, I Jambor, A Lantz, O Ettala, A Stabile, P Taimen, HJ Aronen, ...
European urology oncology 4 (6), 971-979, 2021
612021
Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy
K Lahdensuo, A Erickson, I Saarinen, H Seikkula, J Lundin, M Lundin, ...
Modern Pathology 29 (12), 1565-1574, 2016
592016
Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: a prospective multi-institutional trial
I Jambor, J Verho, O Ettala, J Knaapila, P Taimen, KT Syvänen, ...
PLoS medicine 16 (6), e1002813, 2019
552019
SORLA regulates endosomal trafficking and oncogenic fitness of HER2
M Pietilä, P Sahgal, E Peuhu, NZ Jäntti, I Paatero, E Närvä, H Al-Akhrass, ...
Nature Communications 10 (1), 2340, 2019
542019
Validation of novel biomarkers for prostate cancer progression by the combination of bioinformatics, clinical and functional studies
S Alinezhad, RM Väänänen, J Mattsson, Y Li, T Tallgren, N Tong Ochoa, ...
PloS one 11 (5), e0155901, 2016
542016
The system can't perform the operation now. Try again later.
Articles 1–20